Personalized B-fructan Diet in Inflammatory Bowel Disease Patients
Key facts
- Where
- Edmonton and Winnipeg, CanadaSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 6 and 39 years old?
Source: NCT05615779, who can take part
Where in Canada
- University of Alberta HospitalEdmonton, CanadaTaking people
- Health Sciences Centre HospitalWinnipeg, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Manitoba
- Trial code
- NCT05615779
- Record updated
- 6 April 2025
- Original description
This study aims to examine patient tolerability of personalized dietary fibre consumption recommendations (high-pectin diet versus high-B-fructan diet based on personalized responses), provided by an IBD dietician, based on our novel translational research findings.Read full original descriptionShow less
The Fibre Study: RCT of Personalized Fibre Diet in IBD
This study aims to examine patient tolerability of personalized dietary fibre consumption recommendations (high-pectin diet versus high-B-fructan diet based on personalized responses), provided by an IBD dietician, based on our novel translational research findings.
Inclusion: Children (age 6-17) or young adults (age 18-39); Known or suspected UC or IBDU [there will be 2 control group: non-IBD (undergoing colonoscopy but found not to have IBD; and healthy (no GI symptoms, so not required to have colonoscopy; could be family members)]; For UC: Remission-mild-moderate disease: Mayo score <10; Clinical indication for sedated colonoscopy; Disease location: E2-E4; Stable treatment (not on steroids; biologics or immunomodulator not changed in last month); High likelihood that patients will be able to collect all samples and provide all data.
Exclusion: Documented enteric infection during the 3 months prior to endoscopy; Systemic steroids (above 10 mg/day of Prednisone); Topical therapy within 1 week of endoscopy; History of abdominal surgery, including appendectomy; Presence of non-IBD bowel conditions (e.g., celiac), anatomical or mucosal abnormalities, motility disorder; Presence of a systemic disease requiring treatment (cancer, ischemic heart disease, kidney failure, etc); Use of antibiotics for a week or more over the last 3 months; Use of probiotics or prebiotics at pharmacological doses (adding fibre sources to food or probiotics in yogurt, for example, are allowed); Proctitis (E1); Recent change in IBD treatment (started biologics or IM over the last month); Pregnancy or planning to become pregnant during the study; Inability to understand or sign the consent.